文献速递神经核医学

18F-SMBT-1 PET显像揭示阿尔茨海默病连续谱中星形胶质细胞反应性与Aβ负荷的关系

Astrocyte reactivity across the AD continuum measured by [18F]SMBT-1 and its relationship with the Aβ burden.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-05-06

该多中心研究纳入91例受试者(35例健康对照、44例轻度认知障碍、12例阿尔茨海默病),采用新型MAO-B特异性PET示踪剂18F-SMBT-1联合淀粉样蛋白PET、T1加权MRI及标准化神经心理学评估,发现淀粉样蛋白阳性的MCI和AD组在额叶、颞叶和后扣带回区域18F-SMBT-1摄取显著升高,且区域摄取与Aβ负荷和认知评分相关,提示星形胶质细胞增生可能连接淀粉样病理与认知损害。

要点

  • 18F-SMBT-1在淀粉样蛋白阳性MCI和AD患者额叶、颞叶及后扣带回摄取显著升高。
  • MCI+呈广泛AD样星形胶质细胞增生模式,MCI-呈不同分布特征。
  • 症状性MCI+的18F-SMBT-1摄取显著高于无症状HC+。

核心结论

  • 18F-SMBT-1可刻画Aβ定义的AD连续谱中反应性星形胶质细胞增生的空间模式与程度。
  • 星形胶质细胞增生可能是淀粉样病理与认知损害之间的重要机制环节。

研究设计与样本

  • 多中心研究,共91例参与者(35例HC、44例MCI、12例AD)。
  • 所有参与者接受18F-SMBT-1 PET、淀粉样蛋白PET、T1加权MRI及标准化神经心理学评估。
  • 基于18F-SMBT-1 PET数据,使用四个参考区计算SUVR,按Aβ状态分层进行亚组比较。

主要发现

  • 淀粉样蛋白阳性MCI(MCI+)和AD组在额叶、颞叶和后扣带回区域18F-SMBT-1摄取较淀粉样蛋白阴性HC(HC-)显著升高。
  • MCI+个体呈现广泛AD样星形胶质细胞增生模式,而MCI-组显示不同分布特征。
  • 症状性MCI+个体的18F-SMBT-1摄取显著高于无症状HC+个体。
  • 区域SMBT-1摄取与更大的Aβ负荷和更差的认知评分强相关。

关键数值与推荐

  • 基于18F-SMBT-1 PET数据使用四个参考区计算SUVR,按Aβ状态分层进行亚组比较。

临床怎么用

  • 18F-SMBT-1 PET可用于在体评估AD连续谱中反应性星形胶质细胞增生的空间模式与程度。
  • 星形胶质细胞增生显像可能辅助理解淀粉样病理与认知损害的联系,并支持治疗开发中的潜在应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Astrocytes colocalize with fibrillar amyloid-β (Aβ) plaques in postmortem Alzheimer's disease (AD) brain tissue; however, their spatiotemporal dynamics in vivo remain poorly understood. This multicenter study aimed to investigate the progression of astrocyte reactivity across the AD continuum, including healthy controls (HC), mild cognitive impairment (MCI), and AD, using the novel monoamine oxidase B (MAO-B)-specific PET tracer [18F]SMBT-1, while exploring its association with cognitive performance and amyloid burden. METHODS: A total of 91 participants (35 HC, 44 MCI, 12 AD) underwent [18F]SMBT-1 PET, amyloid PET, T1-weighted MRI, and standardized neuropsychological assessments. Standardized uptake value ratios (SUVRs) were calculated based on [18F]SMBT-1 PET data using four reference regions for subgroup comparisons stratified by Aβ status. RESULTS: [18F]SMBT-1 uptake was significantly elevated in amyloid-positive MCI (MCI+) and AD groups compared with amyloid-negative HC (HC-) in the frontal, temporal, and posterior cingulate regions. Notably, astrogliosis patterns distinguished MCI subtypes: MCI+ individuals exhibited a widespread AD-like pattern, whereas the MCI- group showed a distinct profile. Furthermore, the uptake in symptomatic MCI+ individuals was significantly higher than that in asymptomatic HC+ individuals. Regional SMBT-1 uptake also strongly correlated with greater Aβ burden and worse cognitive scores. CONCLUSION: This study demonstrates that [18F]SMBT-1 is a promising tool for characterizing the spatial pattern and magnitude of reactive astrogliosis across the Aβ-defined AD continuum. Our findings further suggest that astrogliosis may represent an important mechanistic link between amyloid pathology and cognitive impairment, supporting its potential relevance in therapeutic development. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) jRCTs031210602, registered Feb. 07, 2022. URL FOR THE TRIAL REGISTRY: https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031210602 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu Y, Hiraoka K, Mesfin B, et al. Astrocyte reactivity across the AD continuum measured by [18F]SMBT-1 and its relationship with the Aβ burden. Eur J Nucl Med Mol Imaging. 2026. PMID: 42126566. doi:10.1007/s00259-026-07824-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。